Mirae Asset Global Investments Co., Ltd. Ventyx Biosciences, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $20 Billion
- Q2 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 2,105 shares of VTYX stock, worth $4,820. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,105
Previous 13,169
84.02%
Holding current value
$4,820
Previous $72,000
94.44%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding VTYX
# of Institutions
124Shares Held
57.4MCall Options Held
222KPut Options Held
269K-
Deerfield Management Company, L.P. (Series C) New York, NY5.83MShares$13.3 Million0.28% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il5.76MShares$13.2 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA5.25MShares$12 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$10.9 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.17MShares$7.26 Million0.04% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $129M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...